Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.
S. Agraso Busto et al.
J Clin Oncol 37, 2019 (suppl; abstr e20654)
Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.
Comunicaciones en congresosS. Agraso Busto et al.
J Clin Oncol 37, 2019 (suppl; abstr e20654)
Galician lung cancer group: Afatinib’s data as first-line treatment for elderly patients.
Comunicaciones en congresosS. Agraso Busto et al.
J Clin Oncol 37, 2019 (suppl; abstr e20662)
Utility of the Lung Inmune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.
Comunicaciones en congresosJ. Ruiz Bañobre et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20645)
Third and successive-lines of chemotherapy in NSCLC patientes without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón.
Comunicaciones en congresosF. Javier Afonso Afonso et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20579)
Efficacy and safety of Crizotinib in patient with ALK positive non small cell lung cancer (NSCLC): Real-world findings.
Comunicaciones en congresosC. Azpitarte Raposeiras et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20636)
